Evidence map›Paper›PMID 39771502›Full record

ArticlePharmaceutics2024

Toxicological Assessment of 2-Hydroxychalcone-Mediated Photodynamic Therapy: Comparative In Vitro and In Vivo Approaches.

Níura Madalena Bila, Carolina Orlando Vaso, Jenyffie Araújo Belizário, Letícia Ribeiro Assis, Luís Octávio Regasini, Carla Raquel Fontana, Ana Marisa Fusco-Almeida, Caroline Barcelos Costa-Orlandi, Maria José Soares Mendes-Giannini

Abstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Níura Madalena BilaDepartment of Clinical Analysis, School of Pharmaceutical Sciences, Universidade Estadual Paulista (UNESP), Araraquara 14800-903, SP, Brazil.ORCID 0000-0002-4236-3366
Carolina Orlando VasoDepartment of Clinical Analysis, School of Pharmaceutical Sciences, Universidade Estadual Paulista (UNESP), Araraquara 14800-903, SP, Brazil.ORCID 0000-0002-4629-680X
Jenyffie Araújo BelizárioDepartment of Clinical Analysis, School of Pharmaceutical Sciences, Universidade Estadual Paulista (UNESP), Araraquara 14800-903, SP, Brazil.
Letícia Ribeiro AssisDepartment of Chemistry and Environmental Sciences, Institute of Biosciences, Humanities and Exact Sciences, Universidade Estaudal Paulista (UNESP), São José do Rio Preto 01049-010, SP, Brazil.
Luís Octávio RegasiniDepartment of Chemistry and Environmental Sciences, Institute of Biosciences, Humanities and Exact Sciences, Universidade Estaudal Paulista (UNESP), São José do Rio Preto 01049-010, SP, Brazil.ORCID 0000-0001-8574-0670
Carla Raquel FontanaDepartment of Clinical Analysis, School of Pharmaceutical Sciences, Universidade Estadual Paulista (UNESP), Araraquara 14800-903, SP, Brazil.
Ana Marisa Fusco-AlmeidaDepartment of Clinical Analysis, School of Pharmaceutical Sciences, Universidade Estadual Paulista (UNESP), Araraquara 14800-903, SP, Brazil.
Caroline Barcelos Costa-OrlandiDepartment of Clinical Analysis, School of Pharmaceutical Sciences, Universidade Estadual Paulista (UNESP), Araraquara 14800-903, SP, Brazil.ORCID 0000-0002-5752-6367
Maria José Soares Mendes-GianniniDepartment of Clinical Analysis, School of Pharmaceutical Sciences, Universidade Estadual Paulista (UNESP), Araraquara 14800-903, SP, Brazil.ORCID 0000-0002-8059-0826

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 134559/2018-5, 142049/2019- 0Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) 001; 88887.500765/2020-00Fundação de Amparo à Pesquisa do Estado de São Paulo 2019/22188-8, 2020/15586-4, 2021/03805-6, 2017/18388-6, 2018/02785-9Programa de Apoio ao Desenvolvimento Científico (PADC) da Faculdade de Ciências Farma-cêuticas da UNESP 00Pró-Reitoria de Pós-Graduação (PROPG) PDI-UNESP-00
6 · The paper itself

Abstract

backgroundPhotodynamic therapy (PDT) is a treatment modality that uses light to activate a photosensitizing agent, destroying target cells. The growing awareness of the necessity to reduce or eliminate the use of mammals in research has prompted the search for safer toxicity testing models aligned with the new global guidelines and compliant with the relevant regulations.

objectiveThe objective of this study was to assess the impact of PDT on alternative models to mammals, including in vitro three-dimensional (3D) cultures and in vivo, in invertebrate animals, utilizing a potent photosensitizer, 2-hydroxychalcone.

methodsCytotoxicity was assessed in two cellular models: monolayer (2D) and 3D. For this purpose, spheroids of two cell lines, primary dermal fibroblasts (HDFa) and adult human epidermal cell keratinocytes (HaCat), were developed and characterized following criteria on cell viability, shape, diameter, and number of cells. The survival percentages of

resultsThe findings indicated that all the assessed platforms are appropriate for investigating PDT toxicity. Furthermore, 2-hydroxychalcone demonstrated low toxicity in the absence of light and when mediated by PDT across a range of in vitro (2D and 3D cultures) and in vivo (invertebrate animal models, including

conclusionThere was a strong correlation between the in vitro and in vivo tests, with similar toxicity results, particularly in the 3D models and

Indexed as

2-hydroxychalconeCaenorhabditis elegansGalleria mellonellamonolayersphotodynamic therapythree-dimensional tissue modeltoxicological evaluation of compounds

Identifiers

PMID39771502
PMCPMC11728496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.